标题
Precision medicine needs randomized clinical trials
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume 14, Issue 5, Pages 317-323
出版商
Springer Nature
发表日期
2017-02-07
DOI
10.1038/nrclinonc.2017.8
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Rare cancers: a sea of opportunity
- (2016) Niki Boyd et al. LANCET ONCOLOGY
- What have we learned from SHIVA?
- (2016) Christophe Le Tourneau et al. Nature Reviews Clinical Oncology
- Adaptive Randomization of Neratinib in Early Breast Cancer
- (2016) John W. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- I-SPY 2 — A Glimpse of the Future of Phase 2 Drug Development?
- (2016) David Harrington et al. NEW ENGLAND JOURNAL OF MEDICINE
- New insights into the evaluation of randomized controlled trials for rare diseases over a long-term research horizon: a simulation study
- (2016) Mohamed Amine Bayar et al. STATISTICS IN MEDICINE
- Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms
- (2016) Maria Schwaederle et al. JAMA Oncology
- Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials
- (2015) X. Paoletti et al. ANNALS OF ONCOLOGY
- Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials
- (2015) M. R. Theoret et al. CLINICAL CANCER RESEARCH
- Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example
- (2015) J. R. Sachs et al. CLINICAL CANCER RESEARCH
- FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
- (2015) S. Khozin et al. CLINICAL CANCER RESEARCH
- The role of nonrandomized trials in the evaluation of oncology drugs
- (2015) R Simon et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Commentary on Hey and Kimmelman
- (2015) Marc Buyse Clinical Trials
- Are outcome-adaptive allocation trials ethical?
- (2015) Spencer Phillips Hey et al. Clinical Trials
- Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study
- (2015) Laurie H. Sehn et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Cancer Advances 2015: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
- (2015) Gregory A. Masters et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial
- (2015) Ariel Lopez-Chavez et al. JOURNAL OF CLINICAL ONCOLOGY
- Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study
- (2015) Matthew J. Ellis et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials
- (2015) Maria Schwaederle et al. JOURNAL OF CLINICAL ONCOLOGY
- Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort
- (2015) Julien Mazières et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment
- (2015) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Application of Molecular Profiling in Clinical Trials for Advanced Metastatic Cancers
- (2015) S. Kummar et al. JNCI-Journal of the National Cancer Institute
- Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval
- (2015) Denis L. Fontes Jardim et al. JNCI-Journal of the National Cancer Institute
- Expansion platform type II: testing a treatment strategy
- (2015) Daniel V T Catenacci LANCET ONCOLOGY
- Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
- (2015) Christophe Le Tourneau et al. LANCET ONCOLOGY
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- (2015) David M. Hyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- The 21st Century Cures Act — Will It Take Us Back in Time?
- (2015) Jerry Avorn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Application of Molecular Profiling in Clinical Trials for Advanced Metastatic Cancers
- (2015) S. Kummar et al. JNCI-Journal of the National Cancer Institute
- Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval
- (2015) Denis L. Fontes Jardim et al. JNCI-Journal of the National Cancer Institute
- Designs of drug-combination phase I trials in oncology: a systematic review of the literature
- (2014) M.- K. Riviere et al. ANNALS OF ONCOLOGY
- Ethical Considerations for Outcome-adaptive Trial Designs: A Clinical Researcher's Perspective
- (2014) Scott Brian Saxman BIOETHICS
- U.S. Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive
- (2014) S. M. Malik et al. CLINICAL CANCER RESEARCH
- Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses
- (2014) A.-M. Tsimberidou et al. CLINICAL CANCER RESEARCH
- Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents – Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study
- (2014) Sophie Postel-Vinay et al. EUROPEAN JOURNAL OF CANCER
- Discontinued in 2013: oncology drugs
- (2014) Robert Williams EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
- (2014) Mark G. Kris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Improving the Drug Development Process
- (2014) Benjamin Djulbegovic et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Evaluation of Statistical Designs in Phase I Expansion Cohorts: The Dana-Farber/Harvard Cancer Center Experience
- (2014) Suzanne E. Dahlberg et al. JNCI-Journal of the National Cancer Institute
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Determining the optimal dose in the development of anticancer agents
- (2014) Ron H. J. Mathijssen et al. Nature Reviews Clinical Oncology
- Equipoise abandoned? Randomization and clinical trials
- (2013) R. Kurzrock et al. ANNALS OF ONCOLOGY
- Designing Transformative Clinical Trials in the Cancer Genome Era
- (2013) Stefan Sleijfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Evolution of Clinical Trial Design in Early Drug Development: Systematic Review of Expansion Cohort Use in Single-Agent Phase I Cancer Trials
- (2013) Arif Manji et al. JOURNAL OF CLINICAL ONCOLOGY
- Formal Statistical Testing and Inference in Randomized Phase II Trials in Medical Oncology
- (2012) Everardo D. Saad et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials
- (2012) R. Dienstmann et al. MOLECULAR CANCER THERAPEUTICS
- Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
- (2012) Jorge E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor
- (2011) X. Liu et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Trials: A Long-term Investment With Promising Returns
- (2011) M. R. Sharma et al. JNCI-Journal of the National Cancer Institute
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Early Accelerated Approval for Highly Targeted Cancer Drugs
- (2011) Bruce A. Chabner NEW ENGLAND JOURNAL OF MEDICINE
- Rethinking Clinical Trials
- (2011) A. Grove SCIENCE
- The BATTLE Trial: Personalizing Therapy for Lung Cancer
- (2011) Edward S. Kim et al. Cancer Discovery
- Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse
- (2010) R. K. Jain et al. CLINICAL CANCER RESEARCH
- Pharmacokinetics, Pharmacodynamics, and Tolerability of Aleglitazar in Patients With Type 2 Diabetes: Results From a Randomized, Placebo-Controlled Clinical Study
- (2010) P Sanwald-Ducray et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Randomized Phase II Trials: Inevitable or Inadvisable?
- (2010) Hui K. Gan et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of Error Rates in Single-Arm Versus Randomized Phase II Cancer Clinical Trials
- (2010) Hui Tang et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcome-Adaptive Randomization: Is It Useful?
- (2010) Edward L. Korn et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarkers and surrogate end points—the challenge of statistical validation
- (2010) Marc Buyse et al. Nature Reviews Clinical Oncology
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of Agile Designs in First-in-Human (FIH) Trials—A Simulation Study
- (2009) Itay Perlstein et al. AAPS Journal
- The Need for Large-Scale Randomized Evidence Without Undue Emphasis on Small Trials, Meta-analyses, or Subgroup Analyses
- (2009) Charles H. Hennekens JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges
- (2009) Sumithra J. Mandrekar et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose Escalation Methods in Phase I Cancer Clinical Trials
- (2009) Christophe Le Tourneau et al. JNCI-Journal of the National Cancer Institute
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Optimising the design of phase II oncology trials: The importance of randomisation
- (2008) Mark J. Ratain et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now